Back to search
FDAFDA · Food and drugs·Recall number D-0073-2023

Allergy Relief D, Fexofenadine HCL 60mg/Antihistamine, Pseudoephedrine HCL 120mg/Nasal Decongestant, Extended-Release Tablets USP, packaged as (a) 20 count carton NDC 49032-273-20; (b) 30 count carton, NDC49032-273-30; Distributed by: Walmart Inc., Bentonville, AR 72716, Product of India

Published December 7, 2022 · Recall initiated: November 21, 2022

Summary

FDA records drug Class III recall D-0073-2023, published December 7, 2022 and initiated November 21, 2022. Recalling firm: Dr. Reddy's Laboratories, Inc.; Status: Terminated; Reported quantity: 25,176, 30-count; 22,968 20-count; Lot: Lot# (a) AC2203133B, EXP 01/2024; (b) AC2203133A, EXP 01/2024. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed dissolution specifications

What to do

Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Dr. Reddy's Laboratories, Inc.
Distributor
Nationwide in the USA
Lot
Lot# (a) AC2203133B, EXP 01/2024; (b) AC2203133A, EXP 01/2024.
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Allergy Relief D, Fexofenadine HCL 60mg/Antihistamine, Pseudoephedrine HCL 120mg/Nasal Decongestant, Extended-Release Tablets USP, packaged as (a) 20 count carton NDC 49032-273-20; (b) 30 count carton, NDC49032-273-30; Distributed by: Walmart Inc., Bentonville, AR 72716, Product of India recalled?

Yes. FDA published recall D-0073-2023 on December 7, 2022. Reported hazard: Failed dissolution specifications

What should I do if I have this product?

Letter